Key Highlights
- Revenue was USD 12.88 million against a USD 14.02 million estimate, and the loss was USD 0.15 per share.
- Revenue rose about 11% year over year and 13% sequentially, while gross Margin increased to 86.2% from 83.5%.
- Cash was approximately USD 41 million, which management said fully funds its strategic growth plan, per the call.
- CMS finalized a 2027 payment of about USD 20,910 for a mapping angiogram code, up roughly 76%.
TriSalus Life Sciences (NASDAQ:TLSI) reported third quarter 2026 Revenue of USD 12.88 million, below the USD 14.02 million estimate, while loss per share of USD 0.15 was wider than the USD 0.13 estimated loss. Revenue was up about 11% from USD 11.6 million a year earlier and up about 13% from USD 11.4 million in the second quarter, driven by increasing adoption of its TriNav drug delivery device.
Management acknowledged growth came in below its own expectation, citing the timing of its commercial organization transition, new account ramp and a faster shift toward super selective Y90 administration in small distal vessels. It said TriNav Advance, which received FDA 510(k) clearance in September 2026, is intended to address that trend.
Gross profit increased USD 1.4 million, or 14.9%, and gross margin rose to 86.2% from 83.5%. Cost of Goods Sold decreased USD 0.1 million, or 6.5%. General and administrative expenses decreased USD 1.2 million, or 20.4%, while the filing notes higher Marketing and sales organization costs from the sales expansion. The change in Fair Value of SEPA, Warrant and revenue base Redemption liabilities was a loss of USD 0.7 million, against a loss of USD 2.9 million a year earlier. Nine-month revenue rose USD 1.2 million, or 3.9%.
The company ended the quarter with approximately USD 41 million in cash.
Reimbursement Changes
On November 4, CMS published its calendar year 2027 final rules, which the company described as favorable. In the hospital outpatient payment rule, code C8004, covering a Y90 mapping angiogram, was reassigned to a higher payment category. The national Medicare payment for that code rises from about USD 11,874 to about USD 20,910, roughly 76%, effective January 1, 2027. The pressure-enabled drug delivery embolization procedure code, C9797, moves from about USD 18,729 in 2026 to about USD 20,910 in 2027.
Management said these decisions give the approach a payment path in each site of care, including hospital outpatient, ambulatory surgery center and office-based lab settings ahead of a 2027 office-based lab launch. In June 2026 CMS also created a permanent G-code for procedures using a pressure-generating catheter in non-facility settings.
Clinical and Market Context
The company cites a United States addressable market of about USD 2.5 billion across liver embolization and additional indications. It reports 11 active studies across 27 clinical sites, with more than 400 patients treated with TriNav, and a reportable safety event rate of 0.02% across nearly 20,000 device patient uses since its 2020 launch. Enrollment in a prospective study in hypovascular tumors is guided to take about 12 to 18 months.
Items to Follow
Revenue growth after the launch of TriNav Advance, productivity in newly expanded territories, the January 2027 payment changes and cash use are the figures to follow. The filing points readers to a commitments and contingencies note for legal proceedings.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...